AstraZeneca raises stakes in obesity drug race with Eccogene deal
An early-stage China biotech hopes to break into the GLP-1 race for obesity and diabetes as heavyweights dominate the field, with Novo Nordisk already touting Phase III data on its oral GLP-1 and Eli Lilly and Pfizer nearing their big days.
Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence Phase I...